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Objectives: Repetitive transcranial magnetic stimulation (rTMS) seems to be effective
as an antidepressant, however, some confusion remains about the best parameters to
apply and the efﬁcacy of its association with pharmacological antidepressant treatments.
Method: In a single blind randomized study 14 patients with unipolar resistant depression
to one antidepressant treatment were enrolled to receive, in combination with venlafaxine
(150mg), either 20 sessions of 10Hz rTMS (2000 pulses per session) applied over the
left dorsolateral prefrontal cortex (DLPFC) or 20 sessions of 1Hz rTMS (120 stimulations
per sessions) applied over the right DLPFC. Results: A similar antidepressant effect was
observed in both groups with a comparable antidepressant delay of action (2weeks) and a
comparable number of responders (MADRS<15) after 4weeks of daily rTMS sessions (66
vs 50%). Conclusion: Low- and high- frequency rTMS seems to be effective as an add-on
treatment to venlafaxine as monotherapy in pharmacological refractory major depression
(stage 1). Due to its short duration (one session of 1Hz rTMS lasts 4min vs 16 for 10Hz
rTMS)anditssafety,lowfrequencyrTMSmaybeausefulalternativetreatmentforpatients
with refractory depression.
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INTRODUCTION
Depression constitutes a major public health concern with a con-
siderably high level of morbidity and mortality. Although anti-
depressant (AD) treatments have demonstrated their efﬁciency, a
substantial number of depressed patients (50–60%) respond only
partiallyornotatalltoatleastonetrialof anantidepressantmed-
ication(Steffensetal.,1997)andcloseto20%of thesepatientsare
refractory to any antidepressant medication (Fava, 2003). More-
over,the clinical utility of antidepressant drugs is impaired by the
delay in onset of their therapeutic action.
Most of recent studies as well as meta-analysis support an anti-
depressant effect of high frequency (HF) repetitive transcranial
magnetic stimulation (rTMS) applied to the left dorsolateral pre-
frontal cortex (LDLPFC; George et al., 2010; for review: Brunelin
etal.,2007).Howeverthereremainssomeconfusionaboutthebest
beneﬁcialstimulationsitetotargetaswellasthebestparametersto
apply. While the impact of starting a combination between rTMS
and an AD at the same time is still poorly studied, some authors
support the hypothesis that this association could shorten the AD
treatment delay of action (Poulet et al., 2004; Rumi et al., 2005).
Ontheotherhand,thereisgrowingevidencethatHFLDLPFCisas
effective as low frequency (LF) rTMS applied to the right DLPFC
(RDLPFC) in the treatment of depressive episode (Höppner et al.,
2003;Isenbergetal.,2005;Sternetal.,2007;Fitzgeraldetal.,2009;
Pallanti et al.,2010; Rossini et al., 2010).
We report here results from a pilot single blind double arms
controlled study investigating the antidepressant effect, in asso-
ciation with venlafaxine, of active HF (10Hz) LDLPFC rTMS
compared to active LF (1Hz) LDLPFC rTMS (150mg) in patient
with refractory depressive symptoms.
MATERIALS AND METHODS
SixteenpatientswithunipolarmajordepressionaccordingtoDSM
IV were included through clinical and MINI evaluation (Mini
version 4.4). All of them gave their written informed consent
before entering the study which was approved by a regional eth-
ical committee. They were aged between 18 and 65 and have not
tried venlafaxine for the present depression episode. Patients were
recruited at the “Le vinatier” Hospital. At inclusion, all of them
presentaMontgomeryandAsberg(1979)DepressionRatingScale
(MADRS) score >20 despite the prescription of an AD at efﬁ-
cient dose for at least 12weeks. Patients respond to stage 1 of
treatment-resistant depression as described in Fava (2003).
Prospective patients were screened for contraindications to
rTMS, including a history of personal or family seizures, neu-
rological or neurosurgical antecedent, inner ear prosthesis, pace-
maker, and anticonvulsive medication. Electroencephalographic
andclinicalexaminationwasmadebeforetheﬁrstrTMSsequence.
Participants were randomly allocated into two groups after
2weeks of wash out period for all medications. Venlafaxine
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(75mg/day) administration as monotherapy began 3days before
the start of rTMS treatment. The day of the ﬁrst rTMS session,
venlafaxine was increased to 150mg on the morning. Then, one
groupwastreatedwithvenlafaxineandHF-rTMSappliedoverthe
LDLPFC and the second group was treated with venlafaxine and
LF-rTMS applied over the RDLPFC.
StimulationswerecarriedoutusingaMagPro100(Medtronic–
Boulogne–France) stimulator system using ﬁgure-eight 70-mm
coils. Stimulation intensity was 100% of resting motor thresh-
old. Motor threshold was identiﬁed as the minimum magnetic
ﬁeld strength required to produce left thenar muscle activation by
single transcranial magnetic pulses delivered to the motor cortex
for at least 5 of 10 trials. Coil placement was 5cm anterior from
motor cortex (international 10–20 system). Because two patients
withdrewtheirconsentbeforethestartof thetrial,theﬁnalgroups
were:
– High-frequency group (n =6): Stimulation frequency was
10Hz.Eachpatientreceived10,15,or20rTMSsessionsdepend-
ing on the response rate after 10 sessions, one session per day
(2 or 4weeks). Each daily session consisted in a total of 2000
pulses 40 trains of 5s duration and 30s intertrain intervals.
– Low frequency group (n =8): Stimulation frequency was 1Hz.
Each patient received 10, 15, or 20 rTMS sessions depending
on the response rate after 10 sessions, one session per day (2 or
4weeks). Each daily session consisted in a total of 120 pulses of
2 trains of 60s duration and 120s intertrain intervals.
A psychiatrist blind to group assignment conducted all assess-
ments of patients’ symptoms. To assess antidepressant effects, we
used the 10-items MADRS. We measured MADRS scores at base-
line, after 5, 10, 15, and 20 rTMS sessions. Patients who were
responders after the ﬁrst 10 or 15 rTMS sessions (deﬁned as
MADRS score <15) did not received more rTMS sessions.
ANALYSIS
Comparisons between groups at baseline were assessed using stu-
dent t-tests except for gender (Fischer’s chi-square). Statistical
analysis was performed at a signiﬁcant threshold of 0.05 using
a repeated measures analysis of variance (ANOVA) on MADRS
scores at each assessment times. Number of responders was com-
paredbetweenthegroupsusingFischer’schi-squaretest.Statistics
were done using the Statistica software.
RESULTS
At baseline, the two groups did not signiﬁcantly differ for age,
sex ratio, and for MADRS scores (Table 1). No adverse event was
observed in both groups.
Number of responders did not differ in each group at
each assessment (χ2 =0.4; dl=1; p =0.57). First responders
(MADRS<15) were observed after 10 rTMS session in both
groups (Table 1). More than 50% of patients were responders
at the end of the study period (4weeks).
Effect of treatment (time) was signiﬁcant in both group
[F(4,44) =15.42; p <10−7]. No signiﬁcant statistical difference
was observed for MADRS scores between the two groups
[F(1,11) =0.32; p =0.58]. We reported no interaction between
Table 1 | Characteristics of patients throughout the study period.
1Hz(n =8) 10Hz (n =6) p
BASELINE CHARACTERISTICS
Age 46.1 (16.3) 50.8 (9.4) 0.54*
Gender (male/female) 2/6 4/2 0.27
†
Inpatient/outpatient 2/6 2/4 0.9*
MADRS 32.0 (8.0) 29.8 (6.9) 0.59*
AFTER 5 rTMS SESSION
MADRS decrease (%) −15.39 (12.02) −19.78 (10.57)
Responders (%) 0 0
AFTER 10 rTMS SESSION
MADRS decrease (%) −22.18 (22.65) −34.95 (14.95)
Responders (%) 25 50
AFTER 15 rTMS SESSION
MADRS decrease (%) −29.72 (34.79) −47 .11 (19.29)
Responders (%) 37 .5 66.7
AFTER 20 rTMS SESSION
MADRS decrease (%) −51.25 (35.35) −52.96 (21.58)
Responders (%) 50 66.7
rTMS: repetitive transcranial magnetic stimulation/MADRS: Montgomery–
Asberg Depression Rating Scale. Results are given as mean (SD).
*Student t-test;
†Fischer Chi-square test.
Responders were deﬁned as patients with a MADRS score <15.
FIGURE 1 | Changes in MADRS scores following rTMS sessions in
combination with venlafaxine (150mg) in both groups: 1Hz applied
over the right dorsolateral prefrontal cortex (DLPFC)/10Hz applied
over the left DLPFC. rTMS: repetitive transcranial magnetic
stimulation/MADRS: Montgomery–Asberg Depression Rating Scale Results
are given as mean and SE.
group (HF or LF) and time [F(4,44) =0.61; p =0.66], suggesting
that decreases of MADRS scores were comparable in both groups
(Figure 1).
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DISCUSSION
Our results replicate and extend previous ﬁndings showing that
DLPFC LF-rTMS administered on the right side results in a simi-
lareffectcomparedtoleft-sidedDLPFCHF-rTMS(Höppneretal.,
2003; Isenberg et al., 2005; Stern et al., 2007; Fitzgerald et al.,
2009; Pallanti et al., 2010; Rossini et al., 2010). Despite a failure
in response to one previous AD, we reported that some patients
could be considered as responders only 2weeks after the start of
treatment and after 4weeks, more than a half of group could be
qualiﬁed as responders as deﬁned by a MADRS score <15.
In combination with venlafaxine (150mg/day), 120 pulses/
session of LF-rTMS over the RDLPFC (delivered during 4min)
could be as effective as 2000 pulses/session of HF-rTMS over
the left DLPFC (delivered during 16min). As the most serious
potential side effect of rTMS is seizure, and that LF-rTMS may
be protective against it (Theodore et al., 2002), thus, more than
saving the user and patient time, LF-rTMS should be a treatment
of choice for patients.
We have observed no relapse during the study period (4weeks)
but a follow up period is required before any conclusion on
this point. We reported no adverse events in the combination of
medication.
The lack of an arm with placebo venlafaxine in association
with active rTMS and of an arm with active venlafaxine and
sham rTMS are some limitations of our study. However, it has
been reported that 1Hz rTMS is as effective as venlafaxine in
the treatment of resistant depression (Bares et al., 2009). More-
over, it is important to note that in a large randomized controlled
trial using venlafaxine alone (Rush et al., 2006), with a demo-
graphiccomparabledepressedgroup,amongthepatientswhohad
a remission (24.8% of the sample), the mean time to remission
was 5.5±4.7weeks (median, 4.2). We reported more than 50%
decrease of MADRS score after 4weeks of treatment while a 30%
decrease of HDRS was reported in a large study investigating the
impact of venlafaxine after previous AD failure (Baldomero et al.,
2005). On the other hand,as it seems to be the case in our results,
Rumietal.(2005)havereportedthatinadd-ontherapyrTMSmay
be able to accelerate the delay efﬁcacy of AD.
In conclusion, although limited by small sample size and lack
of venlafaxine placebo arm, in a sample of patients who have not
responded to one trial of antidepressant medication, in combi-
nation with venlafaxine 150mg/day, right-sided LF-rTMS seems
as effective as left-sided HF-rTMS. In order to investigate the
real impact of LF-rTMS without any antidepressant treatment
compared to rTMS in add-on therapy with venlafaxine and to
venlafaxine alone, we have started a large multicentric study
(clinicaltrials.gov; NCT00714090).
ACKNOWLEDGMENTS
This work was supported by the Conseil Scientiﬁque de la
Recherche(CSR),CHleVinatier.MondinoMarineheldadoctoral
fellowship from la Région Rhône-Alpes.
REFERENCES
Baldomero, E. B., Ubago, J. G., Cer-
cós, C. L., Ruiloba, J. V., Calvo,
C. G., and López, R. P. (2005).
Venlafaxine extended release versus
conventional antidepressants in the
remission of depressive disorders
afterpreviousantidepressantfailure:
ARGOS study. Depress. Anxiety 22,
68–76.
Bares, M., Kopecek, M., Novak, T.,
Stopkova, P., Sos, P., Kozeny, J.,
Brunovsky, M., and Höschl, C.
(2009). Low frequency (1-Hz),right
prefrontal repetitive transcranial
magnetic stimulation (rTMS) com-
pared with venlafaxine ER in the
treatment of resistant depression:
a double-blind, single-centre, ran-
domized study. J. Affect. Disord. 118,
94–100.
Brunelin, J., Poulet, E., Boeuve, C.,
Zeroug-Vial, H., D’Amato, T.,
and Saoud, M. (2007). Efﬁcacy of
repetitive transcranial magnetic
stimulation (rTMS) in major
depression. Encephale 33, 126–134.
Fava, M. (2003). Diagnosis and
deﬁnition of treatment-resistant
depression. Biol. Psychiatry 53,
649–659.
Fitzgerald, P. B., Hoy, K., Daskalakis, Z.
J., and Kulkarni, J. (2009). A ran-
domized trial of the anti-depressant
effects of low- and high-frequency
transcranial magnetic stimulation
in treatment-resistant depression.
Depress. Anxiety 26, 229–234.
George, M. S., Lisanby, S. H., Avery,
D., McDonald, W. M., Durkalski,
V., Pavlicova, M., Anderson, B.,
Nahas, Z., Bulow, P., Zarkowski, P.,
Holtzheimer, P. E. III, Schwartz,
T., and Sackeim, H. A. (2010).
Daily left prefrontal transcranial
magnetic stimulation therapy for
major depressive disorder: a sham-
controlled randomized trial. Arch.
Gen. Psychiatry 67, 507–516.
Höppner, J., Schulz, M., Irmisch, G.,
Mau, R., Schläfke, D., and Richter,
J. (2003). Antidepressant efﬁcacy
of two different rTMS proce-
dures. High frequency over left ver-
sus low frequency over right pre-
frontal cortex compared with sham
stimulation. Eur. Arch. Psychiatry
Clin. Neurosci. 253, 103–109.
Isenberg, K., Downs, D., Pierce, K.,
Svarakic, D., Garcia, K., Jarvis, M.,
North,C.,andKormos,T.C.(2005).
Low frequency rTMS stimulation
of the right frontal cortex is as
effective as high frequency rTMS
stimulation of the left frontal cortex
for antidepressant-free, treatment-
resistant depressed patients. Ann.
Clin. Psychiatry 17, 153–159.
Montgomery, S. A., and Asberg,
M. (1979). A new depression
scale designed to be sensitive
to change. Br. J. Psychiatry 134,
383–389.
Pallanti, S., Bernardi, S., Di Rollo,
A., Antonini, S., and Quercioli, L.
(2010).Unilaterallowfrequencyver-
sus sequential bilateral repetitive
transcranialmagneticstimulation:is
simplerbetterfortreatmentof resis-
tant depression? Neuroscience 167,
323–328.
Poulet, E., Brunelin, J., Boeuve, C.,
Lerond, J., D’Amato, T., Dalery, J.,
and Saoud, M. (2004). Repetitive
transcranial magnetic stimulation
does not potentiate antidepres-
sant treatment. Eur. Psychiatry 19,
382–383.
Rossini, D., Lucca, A., Magri, L.,
Malaguti,A.,Smeraldi,E.,Colombo,
C., and Zanardi, R. (2010). A
symptom-speciﬁc analysis of the
effect of high-frequency left or low-
frequency right transcranial mag-
netic stimulation over the dorso-
lateral prefrontal cortex in major
depression. Neuropsychobiology 62,
91–97.
Rumi, D. O., Gattaz, W. F., Rigo-
natti, S. P., Rosa, M. A., Fregni,
F., Rosa, M. O., Mansur, C.,
Myczkowski, M. L., Moreno, R.
A., and Marcolin, M. A. (2005).
Transcranial magnetic stimulation
accelerates the antidepressant
effect of amitriptyline in severe
depression: a double-blind placebo-
controlled study. Biol. Psychiatry 57,
162–126.
Rush, A. J., Trivedi, M. H., Wisniewski,
S. R., Stewart, J. W., Nierenberg, A.
A., Thase, M. E., Ritz, L., Biggs, M.
M.,Warden,D.,Luther,J. F.,Shores-
Wilson, K., Niederehe, G., and Fava
M for the STAR*D Study Team.
(2006). Bupropion-SR,sertraline,or
venlafaxine-XRafterfailureof SSRIs
for depression. N .E n g l .J .M e d .354,
1231–1242.
Steffens, D. C., Krishnan, K. R., and
Helms, M. J. (1997). Are SSRIs bet-
terthanTCAs?ComparisonofSSRIs
and TCAs: a meta-analysis. Depress.
Anxiety 6, 10–18.
Stern, W. M., Tormos, J. M., Press, D.
Z.,Pearlman,C.,andPascual-Leone,
A. (2007). Antidepressant effects of
high and low frequency repetitive
transcranial magnetic stimulation
to the dorsolateral prefrontal cor-
tex: a double-blind, randomized,
placebo-controlled trial. J. Neu-
ropsychiatry Clin. Neurosci. 19,
179–186.
Theodore, W. H., Hunter, K., Chen, R.,
Vega-Bermudez, F., Boroojerdi, B.,
www.frontiersin.org March 2012 | Volume 3 | Article 13 | 3Eche et al. Low- vs high-frequency rTMS
Reeves-Tyer, P., Werhahn, K., Kelley,
K. R., and Cohen, L. (2002). Tran-
scranialmagneticstimulationforthe
treatment of seizures: a controlled
study. Neurology 59, 560–562.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 31 October 2011; accepted:
12 February 2012; published online: 07
March 2012.
Citation: Eche J, Mondino M, Haese-
baert F,Saoud M,Poulet EandBrunelin
J (2012) Low- vs high-frequency repet-
itive transcranial magnetic stimulation
as an add-on treatment for refractory
depression. Front. Psychiatry 3:13. doi:
10.3389/fpsyt.2012.00013
This article was submitted to Fron-
tiers in Neuropsychiatric Imaging and
Stimulation, a specialty of Frontiers in
Psychiatry.
Copyright © 2012 Eche, Mondino, Hae-
sebaert, Saoud, Poulet and Brunelin.
This is an open-access article distributed
underthetermsoftheCreativeCommons
Attribution Non Commercial License,
which permits non-commercial use, dis-
tribution, and reproduction in other
forums,providedtheoriginalauthorsand
source are credited.
Frontiers in Psychiatry | Neuropsychiatric Imaging and Stimulation March 2012 | Volume 3 | Article 13 | 4